Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

被引：0

作者：

Takeshi Kato

Yoshinori Kagawa

Yasutoshi Kuboki

Makio Gamoh

Yoshito Komatsu

Hirofumi Yasui

Hironaga Satake

Eiji Oki

Hiroaki Tanioka

Masahito Kotaka

Akitaka Makiyama

Tadamichi Denda

Masahiro Goto

Takayuki Yoshino

Kentaro Yamazaki

Junpei Soeda

Kazunori Shibuya

Masaru Iwata

Koji Oba

Kensei Yamaguchi

机构：

[1] National Hospital Organization Osaka National Hospital,Gastroenterological Chemotherapy Department

[2] Kansai Rosai Hospital,Cancer Treatment Center

[3] National Cancer Center Hospital East,undefined

[4] Osaki Citizen Hospital,undefined

[5] Furukawa Honami,undefined

[6] Hokkaido University Hospital,undefined

[7] Shizuoka Cancer Center,undefined

[8] Kobe City Medical Center General Hospital,undefined

[9] Kyushu University,undefined

[10] Okayama Rosai Hospital,undefined

[11] Sano Hospital,undefined

[12] Japan Community Healthcare Organization Kyushu Hospital,undefined

[13] Gifu University Hospital,undefined

[14] Chiba Cancer Center,undefined

[15] Osaka Medical College Hospital,undefined

[16] Takeda Pharmaceutical Company,undefined

[17] University of Tokyo,undefined

[18] Cancer Institute Hospital of Japanese Foundation for Cancer Research,undefined

[19] Kansai Medical University Hospital,undefined

[20] Medical Oncology Kawasaki Medical School,undefined

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Salvage line; Anti-EGFR antibody; Phase 1/2 clinical trial; Oral nucleoside anti-tumour agent; Outcomes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1238 / 1247

页数：9

共 50 条

[31] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
A F Hezel
M S Noel
J N Allen
T A Abrams
M Yurgelun
J E Faris
L Goyal
J W Clark
L S Blaszkowsky
J E Murphy
H Zheng
A A Khorana
G C Connolly
O Hyrien
A Baran
M Herr
K Ng
S Sheehan
D J Harris
E Regan
D R Borger
A J Iafrate
C Fuchs
D P Ryan
A X Zhu
British Journal of Cancer, 2014, 111 : 430 - 436
[32] Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
Hezel, A. F.
Noel, M. S.
Allen, J. N.
Abrams, T. A.
Yurgelun, M.
Faris, J. E.
Goyal, L.
Clark, J. W.
Blaszkowsky, L. S.
Murphy, J. E.
Zheng, H.
Khorana, A. A.
Connolly, G. C.
Hyrien, O.
Baran, A.
Herr, M.
Ng, K.
Sheehan, S.
Harris, D. J.
Regan, E.
Borger, D. R.
Iafrate, A. J.
Fuchs, C.
Ryan, D. P.
Zhu, A. X.
BRITISH JOURNAL OF CANCER, 2014, 111 (03) : 430 - 436
[33] Phase II study of panitumumab monotherapy in chemotherapy-naive frail or elderly patients with unresectable, RAS wild-type colorectal cancer: OGSG 1602
Ohta, Katsuya
Kato, Takeshi
Goto, Masahiro
Terazawa, Tetsuji
Noura, Shingo
Satake, Hironaga
Kagawa, Yoshinori
Kawakami, Hisato
Hasegawa, Hiroko
Yanagihara, Kazuhiro
Shingai, Tatsushi
Nakata, Ken
Kotaka, Masahito
Hiraki, Masayuki
Konishi, Ken
Nakae, Shiro
Sakai, Daisuke
Kurokawa, Yukinori
Shimokawa, Toshio
Satoh, Taroh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[34] Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
Kennecke, H.
Chen, L.
Blanke, C. D.
Cheung, W. Y.
Schaff, K.
Speers, C.
CURRENT ONCOLOGY, 2013, 20 (06) : 326 - 332
[35] Clinical practice use of panitumumab combined with chemotherapy in patients with wild-type RAS metastatic colorectal cancer.
Hebart, Holger Frithjof
Tomasek, Jiri
Csoszi, Tibor
Koukakis, Reija
Kafatos, George
Kuhn, Anja
Bjorklof, Katja
Buchler, Tomas
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[36] TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
Borelli, Beatrice
Moretto, Roberto
Lonardi, Sara
Bonetti, Andrea
Antoniotti, Carlotta
Pietrantonio, Filippo
Masi, Gianluca
Burgio, Valentina
Marmorino, Federica
Salvatore, Lisa
Rossini, Daniele
Zaniboni, Alberto
Zucchelli, Gemma
Martignetti, Angelo
Di Battista, Monica
Pella, Nicoletta
Passardi, Alessandro
Boccaccino, Alessandra
Leone, Francesco
Colombo, Camilla
Granetto, Cristina
Vannini, Francesca
Marsico, Valentina Angela
Martinelli, Erika
Antonuzzo, Lorenzo
Vitello, Stefano
Delliponti, Laura
Boni, Luca
Cremolini, Chiara
Falcone, Alfredo
ESMO OPEN, 2018, 3 (04)
[37] A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
Elena Elez
Carles Pericay
Manuel Valladares-Ayerbes
Inmaculada Bando
Maria Jose Safont
Javier Gallego
Cristina Grávalos
Antonio Arrivi
Alfredo Carrato
Verónica Conde
Maria José Ortiz
Carlos López
Beatriz Alonso
Inmaculada Ruiz de Mena
Eduardo Díaz-Rubio
Josep Tabernero
Enrique Aranda
British Journal of Cancer, 2019, 121 : 378 - 383
[38] A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
Elez, Elena
Pericay, Caries
Valladares-Ayerbes, Manuel
Bando, Inmaculada
Safont, Maria Jose
Gallego, Javier
Gravalos, Cristina
Arrivi, Antonio
Carrato, Alfredo
Conde, Veronica
Jose Ortiz, Maria
Lopez, Carlos
Alonso, Beatriz
Ruiz de Mena, Inmaculada
Diaz-Rubio, Eduardo
Tabernero, Josep
Aranda, Enrique
BRITISH JOURNAL OF CANCER, 2019, 121 (05) : 378 - 383
[39] Regorafenib and trifluridine/tipiracil efficacy and safety in chemorefractory metastatic colorectal cancer patients: A single Bulgarian centre retrospective study
Penkova, M.
Stoyanov, D.
Panayotova, T.
Donev, I.
Petrova, M.
Conev, N.
ANNALS OF ONCOLOGY, 2020, 31 : S100 - S100
[40] A multicenter phase II trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial
Masuishi, T.
Izawa, N.
Takahashi, N.
Shoji, H.
Yamamoto, Y.
Matsumoto, T.
Sugiyama, K.
Kajiwara, T.
Kawakami, K.
Aomatsu, N.
Kondoh, C.
Kawakami, H.
Takegawa, N.
Esaki, T.
Narita, Y.
Hara, H.
Sunakawa, Y.
Boku, N.
Moriwaki, T.
Shimokawa, M.
Nakajima, T.
Muro, K.
ANNALS OF ONCOLOGY, 2021, 32 : S210 - S211

← 1 2 3 4 5 →